Please login to the form below

Not currently logged in
Email:
Password:

Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

Data monitoring committee has not yet conducted any interim efficacy analysis of the shot

During an earnings call for the company’s third quarter results, Pfizer’s chief executive officer Albert Bourla said a data monitoring committee has not yet conducted any interim efficacy analysis of the company’s potential COVID-19 shot.

Previously, Pfizer and its partner BioNTech had planned to seek regulatory approval for the COVID-19 vaccine, BNT162b2, this month.

However, in an open letter published last week, Bourla said that the companies will not submit the vaccine for emergency use authorisation in the US until the third week of November.

In an earnings call yesterday, Bourla reiterated this timeline, adding that “in [the] case of a conclusive readout, positive or negative, we will inform the public as soon as we complete the necessary administrative work, which we estimate to be completed within one week from the time we know”.

"We may know whether or not the vaccine demonstrates efficacy soon," he added.

Aside from details about the timelines for the COVID-19 vaccine, Pfizer’s third quarter earnings report showed a slip in earnings to $12.13bn, a decrease of 4% from last year. According to The Motley Fool, this figure missed the average analyst expectation of $12.33bn.

Net income also dropped significantly in the third quarter of 2020, with Pfizer reporting $2.19bn in the most current quarter compared to a net income of $7.7bn for the same period last year.

Revenues from its generics business Upjohn also dropped by 18% operationally to $1.91bn compared to $2.35bn in the third quarter last year.

This was driven by competition for epilepsy drug Lyrica (pregabalin) in the US, as well as lower revenue for key drugs in China due to the impact from the country’s new volume-based procurement programme.

The negative impact of COVID-19 on Pfizer’s earnings represented approximately $500m, the company added.

This was primarily due to lower demand for certain products in China, as well as disruptions to doctor visits in the US which negatively impacted prescribing patterns for some of its drugs.

One bright spot was an increase in revenues for Pfizer’s biopharma business, which climbed 4% to $10.2bn in the third quarter.

This increase was helped by a 125% increase in global revenues for its rare disease med Vyndaqel (tafamidis), totalling $351m.

Global revenues for its biosimilar also reach $424m, up 80% operationally, driven mostly by recent oncology launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) in the US and other global markets.

Pfizer has now tightened its full-year revenue guidance to a range of $48.8bn to $49.5bn from a previously reported outlook of between $48.6bn to $50.6bn.

Article by
Lucy Parsons

28th October 2020

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....